The emerging role of PARP inhibitors in prostate cancer: A narrative review
Cancer Treatment Reviews · 2025-11 · 140 · 103000
DOI: 10.1016/j.ctrv.2025.103000 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-11. Verfasst von Lorenzo Lobianco und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address: lorenzo.lobianco@isti…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Prostate cancer (PC) is the second most common cancer and the fifth leading cause of cancer mortality in men, worldwide. Genomic analysis identified alterations in DNA damage repair (DDR) pathways, in up to 30% of metastatic castration-resistant prostate cancer (mCRPC). Homologous recombination repair (HRR) mutations in BRCA1/2 emerged as a relevant biomarker in PC, linked to aggressive behavior, unfavorable outcomes and notable responses to poly-ADP ribose polymerase inhibitors (PARPi). While PARPi efficacy in BRCA-mutated mCRPC is well established, their role in earlier disease stages is currently under investigation. This non-systematic narrative review aims to summarize current evidence on PARPi in PC, outlining approved indications, ongoing clinical trials, and emerging therapeutic strategies across different disease settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address: lorenzo.lobianco@istitutotumori.na.it.
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy. Electronic address:…
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address: s.cecere@istitutotumori.na.it.
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address: j.ventriglia@istitutotumori.na.it.
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address: c.pisano@istitutotumori.na.it.
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy. Electronic address: s.rossetti@istitutotumori.na.it.
Zitieren
APA
Lobianco, L., Calvanese, G., D'Ausilio, D., Rossetti, S., Cecere, S. C., Ventriglia, J., Pisano, C., Tambaro, R., Napoli, M. D., Passarelli, A., Roma, C., Luca, A., Sepe, F., Cozzolino, S., Perri, E., Lamia, M. R., Moccia, C., & Pignata, S. (2025). The emerging role of PARP inhibitors in prostate cancer: A narrative review. Cancer Treatment Reviews, 140, 103000. https://doi.org/10.1016/j.ctrv.2025.103000
Vancouver
Lobianco L, Calvanese G, D'Ausilio D, Rossetti S, Cecere SC, Ventriglia J, et al. The emerging role of PARP inhibitors in prostate cancer: A narrative review. Cancer Treatment Reviews. 2025;140:103000. doi:10.1016/j.ctrv.2025.103000
BibTeX
@article{Lobianco2025,
author = {Lobianco, Lorenzo and Calvanese, Gabriele and D'Ausilio, Debora and Rossetti, Sabrina and Cecere, Sabrina Chiara and Ventriglia, Jole and Pisano, Carmela and Tambaro, Rosa and Napoli, Marilena Di and Passarelli, Anna and Roma, Cristin and Luca, Antonella De and Sepe, Filippo and Cozzolino, Silvana and Perri, Erica and Lamia, Maria Rosaria and Moccia, Carlo and Pignata, Sandro},
title = {The emerging role of PARP inhibitors in prostate cancer: A narrative review},
journal = {Cancer Treatment Reviews},
year = {2025},
volume = {140},
pages = {103000},
doi = {10.1016/j.ctrv.2025.103000}
}
EUVIMED